Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant.

Blood
Els LiermanJan Cools

Abstract

The FIP1L1-PDGFRA oncogene is a common cause of chronic eosinophilic leukemia (CEL), and encodes an activated tyrosine kinase that is inhibited by imatinib. FIP1L1-PDGFRA-positive patients with CEL respond to low-dose imatinib therapy, but resistance due to acquired T674I mutation has been observed. We report here the identification of sorafenib as a potent inhibitor of the FIP1 like 1-platelet-derived growth factor receptor alpha (FIP1L1-PDGFRalpha) (T674I) mutant. Sorafenib inhibited the proliferation of FIP1L1-PDGFRalpha and FIP1L1-PDGFRalpha(T674I)-transformed Ba/F3 cells and induced apoptosis of the EOL-1 cell line at a low nanomolar concentration. Western blot analysis confirmed that these effects were due to a direct effect on FIP1L1-PDGFRalpha and FIP1L1-PDGFRalpha(T674I). Sorafenib was recently approved for the treatment of renal cell carcinoma. Our data suggest that low doses of sorafenib could be efficient for the treatment of FIP1L1-PDGFRA-positive CEL and could be used to overcome resistance to imatinib associated with the T674I mutation.

References

Sep 22, 2001·Endocrine-related Cancer·J F LyonsG Bollag
May 25, 2002·Human Molecular Genetics·E Joanna BaxterNicholas C P Cross
Jun 6, 2002·Lancet·Gerald J GleichJoseph H Butterfield
Jun 17, 2003·Proceedings of the National Academy of Sciences of the United States of America·John H GriffinRoger Briesewitz
Dec 23, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dirk StrumbergSiegfried Seeber
Feb 16, 2005·Nature Biotechnology·Miles A FabianDavid J Lockhart
May 5, 2005·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Jan CoolsPeter Marynen
Jul 28, 2005·Proceedings of the National Academy of Sciences of the United States of America·Todd A CarterDavid J Lockhart
Jan 7, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Lillian L SiuMalcolm J Moore
Feb 9, 2006·British Journal of Cancer·P H PatelR J Motzer
Dec 13, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J Motzer, Ronald M Bukowski
Sep 18, 2007·Immunology and Allergy Clinics of North America·Barbara J Bain, Sarah H Fletcher

❮ Previous
Next ❯

Citations

Apr 22, 2008·Molecular Diagnosis & Therapy·Riccardo Colombo, Jürgen Moll
May 1, 2007·Current Hematologic Malignancy Reports·Sonja BurgstallerNicholas C P Cross
Jan 1, 2008·Current Hematologic Malignancy Reports·Animesh Pardanani, Ayalew Tefferi
Jan 30, 2009·Journal of the National Cancer Institute·Tiziana NegriElena Tamborini
Jan 15, 2010·Current Opinion in Hematology·Jason Gotlib
Feb 19, 2009·International Journal of Clinical Practice·C W KhooG Y H Lip
Jun 30, 2010·International Journal of Clinical Practice·J M Walenga, C Adiguzel
Jul 28, 2009·Annual Review of Medicine·Amy Klion
Aug 21, 2009·Blood·Amy D Klion
Dec 24, 2013·Cell Communication and Signaling : CCS·Carl-Henrik Heldin
Sep 13, 2007·Orphanet Journal of Rare Diseases·Florence E RoufosseElie Cogan
May 10, 2011·International Journal of Biological Sciences·Naoki Oishi, Xin Wei Wang
Dec 14, 2007·Proceedings of the National Academy of Sciences of the United States of America·Oleg FedorovStefan Knapp
Jun 6, 2012·Molecular Cancer Therapeutics·Michael C HeinrichJonathan A Fletcher
Jan 6, 2007·Leukemia·D AuclairS M Wilhelm
Sep 21, 2012·Expert Review of Hematology·Valentina GianfeliciJan Cools
Jul 12, 2012·Expert Review of Hematology·Elie Cogan, Florence Roufosse
Sep 19, 2009·Expert Review of Anticancer Therapy·Els Lierman, Jan Cools
Jun 14, 2008·Expert Opinion on Investigational Drugs·Alfonso Quintás-Cardama, Jorge Cortes
Jan 7, 2014·Critical Reviews in Oncology/hematology·M A RahmanA K-Y Lam
Dec 1, 2013·Surgical Pathology Clinics·Ryan C Johnson, Tracy I George
Mar 28, 2012·Seminars in Hematology·J H Butterfield, C R Weiler
Mar 17, 2010·American Journal of Clinical Pathology·Jeffery M KlcoJohn L Frater
Jul 17, 2009·American Journal of Clinical Pathology·Juergen Thiele
Mar 23, 2010·La Revue de médecine interne·J-E KahnO Blétry
Feb 10, 2009·La Revue de médecine interne·J-V MalfusonT de Revel
Dec 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·H RichlyD Strumberg
Nov 26, 2008·Best Practice & Research. Clinical Rheumatology·Jean-Emmanuel KahnLoïc Guillevin
Dec 19, 2007·Biochemical and Biophysical Research Communications·Kenji IshiharaNoriyasu Hirasawa

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis